Affiliation:
1. I. M. Sechenov First Moscow State Medical University
Abstract
Coronavirus disease 2019 (COVID-19) is a disease characterized by diverse clinical manifestations, the severity of which can vary from asymptomatic to extremely severe. At this stage, the urgent task is the early detection of reliable markers of its severity in the acute period of infection and possible changes that cause symptoms in the post-COVID period. The severe COVID-19 is associated with extensive damage to the lungs, pulmonary vessels, and cardiovascular system. In this regard, it seems natural to study the problem of pulmonary hypertension (PH) and right ventricular dysfunction (RVD) in patients with COVID-19, and their significance for assessing the severity of the condition and prognosis. Also important is the availability of reliable non-invasive diagnostics. This review presents data on the incidence of PH and RVD and their potential significance in patients with COVID-19. We have analyzed literature sources in the eLIBRARY, PubMed/MEDLINE, ScienceDirect and ProQuest databases.
Subject
Cardiology and Cardiovascular Medicine
Reference47 articles.
1. WHO. Novel Coronavirus. Situation Report — 205, 2020;205(6):1-19. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. doi:10.1016/S0140-6736(20)30183-5.
3. World Health Organization Press Conference. The World Health Organization (WHO) Has Officially Named the Disease Caused by the Novel Coronavirus as COVID-19. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it (accessed on 11 March 2020).
4. Sulica R, Cefali F, Motschwiller C, et al. COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City. Diagnostics. 2021;11(1):128. doi:10.3390/diagnostics11010128.
5. Humbert M, Kovacs G, Hoeper M, et al. ESC/ERS Scientific Document Group, 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). European Heart Journal. 2022;43(38):3618-731. doi:10.1093/eurheartj/ehac237.